← Leaderboards
Jennifer A Maynard
Stanford University
$5,971,371
Attributed
$8,635,848
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $787.4K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,635,848 · 11
By mechanism
R01$5,975,443 · 3
R21$2,447,523 · 6
S10$171,274 · 1
F32$41,608 · 1
Top collaborators
- Jason Scott Mclellan5 shared
- Raquel L Lieberman4 shared
- Eric T. Harvill3 shared
- Keith P. Johnston2 shared
- Thomas Truskett2 shared
Most similar at Stanford University
Same institution · by research overlap
- Taia Wang$9,240,417
- Gabriel Ozorowski$8,776
- Roger D Kornberg$34,073,673
- Steven R Jordan$5,616
- William I Weis$26,357,228
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsAntibodiesCellsVariantInterestEpitopesBiochemicalIn VitroComplexStructureInsightBindingProtein EngineeringEngineeringMolecularAffinityDesignVaccinesInfectionMortalityFutureImmune ResponseMorbidity - Disease RateReceptor
Grant awards (30)
Structure, function and antigenicity of B. pertussis virulence factors$564,342
R01 · FY2025 · AI
Engineering potent antibodies against human cytomegalovirus$219,127
R21 · FY2025 · AI · contact PI
Structure, function and antigenicity of B. pertussis virulence factors$564,342
R01 · FY2024 · AI
Engineering potent antibodies against human cytomegalovirus$186,279
R21 · FY2024 · AI · contact PI
Structure, function and antigenicity of B. pertussis virulence factors$564,342
R01 · FY2023 · AI
Structure, function and antigenicity of B. pertussis virulence factors$564,342
R01 · FY2022 · AI
Structure, function and antigenicity of B. pertussis virulence factors$564,342
R01 · FY2021 · AI
Recombinant antibodies to differentiate among the many conformations of glaucoma-associated myocilin$223,016
R21 · FY2021 · EY · contact PI
Systematic evaluation of B. pertussis ACTâs role as a protective antigen$374,533
R01 · FY2020 · AI · contact PI
Recombinant antibodies to differentiate among the many conformations of glaucoma-associated myocilin$205,237
R21 · FY2020 · EY · contact PI
Engineered receptors for CMV-targeted adoptive T cell immunotherapy$184,904
R21 · FY2020 · AI · contact PI
Systematic evaluation of B. pertussis ACTâs role as a protective antigen$375,137
R01 · FY2019 · AI · contact PI
Engineered receptors for CMV-targeted adoptive T cell immunotherapy$224,029
R21 · FY2019 · AI · contact PI
Systematic evaluation of B. pertussis ACTâs role as a protective antigen$375,718
R01 · FY2018 · AI · contact PI
Systematic evaluation of B. pertussis ACTâs role as a protective antigen$376,277
R01 · FY2017 · AI · contact PI
Systematic evaluation of B. pertussis ACTâs role as a protective antigen$390,565
R01 · FY2016 · AI · contact PI
Protein nanoclusters for delivery of high concentration therapeutic antibodies$218,825
R21 · FY2015 · AI · contact PI
Protein nanoclusters for delivery of high concentration therapeutic antibodies$180,816
R21 · FY2014 · AI · contact PI
Engineered antibody fragments for cocrystallization with signal peptide peptidase$5,437
R01 · FY2014 · GM · contact PI
Engineered antibody fragments for cocrystallization with signal peptide peptidase$288,090
R01 · FY2013 · GM · contact PI
Returning to the workforce supplement request for R01 GM095638$73,976
R01 · FY2013 · GM · contact PI
Engineered antibody fragments for cocrystallization with signal peptide peptidase$297,000
R01 · FY2012 · GM · contact PI
Engineered antibody fragments for cocrystallization with signal peptide peptidase$297,000
R01 · FY2011 · GM · contact PI
Crystal structure of signal peptide peptidase with engineered antibody fragment$213,061
R21 · FY2011 · DK
Engineered antibody fragments for cocrystallization with signal peptide peptidase$300,000
R01 · FY2010 · GM · contact PI
Crystal structure of signal peptide peptidase with engineered antibody fragment$190,515
R21 · FY2010 · DK
Instrument to quantify solution binding kinetics for drug discovery & development$171,274
S10 · FY2010 · RR · contact PI
Antibody-mediated protection against whooping cough$217,579
R21 · FY2006 · AI · contact PI
Antibody-mediated protection against whooping cough$184,135
R21 · FY2005 · AI
Bacterial Adenylate Cyclase Toxins: Role in Pathogenesis$41,608
F32 · FY2003 · AI